[
    {
        "activityscore": {
            "CYP2D6": "\u22653"
        },
        "allelestatus": {},
        "classification": "Moderate",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "drug": {
            "name": "ondansetron"
        },
        "drugid": "RxNorm:26225",
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352202,
        "implications": {
            "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "lookupkey": {
            "CYP2D6": "\u22653"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "\u22656"
        },
        "allelestatus": {},
        "classification": "Moderate",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "drug": {
            "name": "ondansetron"
        },
        "drugid": "RxNorm:26225",
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352196,
        "implications": {
            "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "lookupkey": {
            "CYP2D6": "\u22656"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "\u22655"
        },
        "allelestatus": {},
        "classification": "Moderate",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "drug": {
            "name": "ondansetron"
        },
        "drugid": "RxNorm:26225",
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352197,
        "implications": {
            "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "lookupkey": {
            "CYP2D6": "\u22655"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "\u22654.5"
        },
        "allelestatus": {},
        "classification": "Moderate",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "drug": {
            "name": "ondansetron"
        },
        "drugid": "RxNorm:26225",
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352198,
        "implications": {
            "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "lookupkey": {
            "CYP2D6": "\u22654.5"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "\u22654"
        },
        "allelestatus": {},
        "classification": "Moderate",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "drug": {
            "name": "ondansetron"
        },
        "drugid": "RxNorm:26225",
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352199,
        "implications": {
            "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "lookupkey": {
            "CYP2D6": "\u22654"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "\u22653.5"
        },
        "allelestatus": {},
        "classification": "Moderate",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "drug": {
            "name": "ondansetron"
        },
        "drugid": "RxNorm:26225",
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352200,
        "implications": {
            "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "lookupkey": {
            "CYP2D6": "\u22653.5"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "\u22653.25"
        },
        "allelestatus": {},
        "classification": "Moderate",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "drug": {
            "name": "ondansetron"
        },
        "drugid": "RxNorm:26225",
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352201,
        "implications": {
            "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "lookupkey": {
            "CYP2D6": "\u22653.25"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "n/a"
        },
        "allelestatus": {},
        "classification": "No recommendation.",
        "comments": "n/a",
        "drug": {
            "name": "ondansetron"
        },
        "drugid": "RxNorm:26225",
        "drugrecommendation": "No recommendation.",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352217,
        "implications": {
            "CYP2D6": "n/a"
        },
        "lookupkey": {
            "CYP2D6": "n/a"
        },
        "phenotypes": {
            "CYP2D6": "Indeterminate"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "4.0"
        },
        "allelestatus": {},
        "classification": "Moderate",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "drug": {
            "name": "ondansetron"
        },
        "drugid": "RxNorm:26225",
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352203,
        "implications": {
            "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "lookupkey": {
            "CYP2D6": "4"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "3.5"
        },
        "allelestatus": {},
        "classification": "Moderate",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "drug": {
            "name": "ondansetron"
        },
        "drugid": "RxNorm:26225",
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352204,
        "implications": {
            "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "lookupkey": {
            "CYP2D6": "3.5"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "3.0"
        },
        "allelestatus": {},
        "classification": "Moderate",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "drug": {
            "name": "ondansetron"
        },
        "drugid": "RxNorm:26225",
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352205,
        "implications": {
            "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "lookupkey": {
            "CYP2D6": "3"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "2.5"
        },
        "allelestatus": {},
        "classification": "Moderate",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "drug": {
            "name": "ondansetron"
        },
        "drugid": "RxNorm:26225",
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352206,
        "implications": {
            "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "lookupkey": {
            "CYP2D6": "2.5"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "2.25"
        },
        "allelestatus": {},
        "classification": "Strong",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "drug": {
            "name": "ondansetron"
        },
        "drugid": "RxNorm:26225",
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352207,
        "implications": {
            "CYP2D6": "Normal metabolism"
        },
        "lookupkey": {
            "CYP2D6": "2.25"
        },
        "phenotypes": {
            "CYP2D6": "Normal Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "2.0"
        },
        "allelestatus": {},
        "classification": "Strong",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "drug": {
            "name": "ondansetron"
        },
        "drugid": "RxNorm:26225",
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352208,
        "implications": {
            "CYP2D6": "Normal metabolism"
        },
        "lookupkey": {
            "CYP2D6": "2"
        },
        "phenotypes": {
            "CYP2D6": "Normal Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "1.75"
        },
        "allelestatus": {},
        "classification": "Strong",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "drug": {
            "name": "ondansetron"
        },
        "drugid": "RxNorm:26225",
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352209,
        "implications": {
            "CYP2D6": "Normal metabolism"
        },
        "lookupkey": {
            "CYP2D6": "1.75"
        },
        "phenotypes": {
            "CYP2D6": "Normal Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "1.5"
        },
        "allelestatus": {},
        "classification": "Strong",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "drug": {
            "name": "ondansetron"
        },
        "drugid": "RxNorm:26225",
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352210,
        "implications": {
            "CYP2D6": "Normal metabolism"
        },
        "lookupkey": {
            "CYP2D6": "1.5"
        },
        "phenotypes": {
            "CYP2D6": "Normal Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "1.25"
        },
        "allelestatus": {},
        "classification": "Strong",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "drug": {
            "name": "ondansetron"
        },
        "drugid": "RxNorm:26225",
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352211,
        "implications": {
            "CYP2D6": "Normal metabolism"
        },
        "lookupkey": {
            "CYP2D6": "1.25"
        },
        "phenotypes": {
            "CYP2D6": "Normal Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "1.0"
        },
        "allelestatus": {},
        "classification": "No recommendation.",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "drug": {
            "name": "ondansetron"
        },
        "drugid": "RxNorm:26225",
        "drugrecommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352212,
        "implications": {
            "CYP2D6": "Very limited data available for CYP2D6 intermediate metabolizers"
        },
        "lookupkey": {
            "CYP2D6": "1"
        },
        "phenotypes": {
            "CYP2D6": "Intermediate Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "0.75"
        },
        "allelestatus": {},
        "classification": "No recommendation.",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "drug": {
            "name": "ondansetron"
        },
        "drugid": "RxNorm:26225",
        "drugrecommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352213,
        "implications": {
            "CYP2D6": "Very limited data available for CYP2D6 intermediate metabolizers"
        },
        "lookupkey": {
            "CYP2D6": "0.75"
        },
        "phenotypes": {
            "CYP2D6": "Intermediate Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "0.5"
        },
        "allelestatus": {},
        "classification": "No recommendation.",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "drug": {
            "name": "ondansetron"
        },
        "drugid": "RxNorm:26225",
        "drugrecommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352214,
        "implications": {
            "CYP2D6": "Very limited data available for CYP2D6 intermediate metabolizers"
        },
        "lookupkey": {
            "CYP2D6": "0.5"
        },
        "phenotypes": {
            "CYP2D6": "Intermediate Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "0.25"
        },
        "allelestatus": {},
        "classification": "No recommendation.",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "drug": {
            "name": "ondansetron"
        },
        "drugid": "RxNorm:26225",
        "drugrecommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352215,
        "implications": {
            "CYP2D6": "Very limited data available for CYP2D6 intermediate metabolizers"
        },
        "lookupkey": {
            "CYP2D6": "0.25"
        },
        "phenotypes": {
            "CYP2D6": "Intermediate Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "0.0"
        },
        "allelestatus": {},
        "classification": "No recommendation.",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "drug": {
            "name": "ondansetron"
        },
        "drugid": "RxNorm:26225",
        "drugrecommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352216,
        "implications": {
            "CYP2D6": "Very limited data available for CYP2D6 poor metabolizers"
        },
        "lookupkey": {
            "CYP2D6": "0"
        },
        "phenotypes": {
            "CYP2D6": "Poor Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "\u22656"
        },
        "allelestatus": {},
        "classification": "Moderate",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "drug": {
            "name": "tropisetron"
        },
        "drugid": "RxNorm:27392",
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352218,
        "implications": {
            "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "lookupkey": {
            "CYP2D6": "\u22656"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "\u22655"
        },
        "allelestatus": {},
        "classification": "Moderate",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "drug": {
            "name": "tropisetron"
        },
        "drugid": "RxNorm:27392",
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352219,
        "implications": {
            "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "lookupkey": {
            "CYP2D6": "\u22655"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "\u22654.5"
        },
        "allelestatus": {},
        "classification": "Moderate",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "drug": {
            "name": "tropisetron"
        },
        "drugid": "RxNorm:27392",
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352220,
        "implications": {
            "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "lookupkey": {
            "CYP2D6": "\u22654.5"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "\u22654"
        },
        "allelestatus": {},
        "classification": "Moderate",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "drug": {
            "name": "tropisetron"
        },
        "drugid": "RxNorm:27392",
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352221,
        "implications": {
            "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "lookupkey": {
            "CYP2D6": "\u22654"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "\u22653.5"
        },
        "allelestatus": {},
        "classification": "Moderate",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "drug": {
            "name": "tropisetron"
        },
        "drugid": "RxNorm:27392",
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352222,
        "implications": {
            "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "lookupkey": {
            "CYP2D6": "\u22653.5"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "\u22653.25"
        },
        "allelestatus": {},
        "classification": "Moderate",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "drug": {
            "name": "tropisetron"
        },
        "drugid": "RxNorm:27392",
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352223,
        "implications": {
            "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "lookupkey": {
            "CYP2D6": "\u22653.25"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "\u22653"
        },
        "allelestatus": {},
        "classification": "Moderate",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "drug": {
            "name": "tropisetron"
        },
        "drugid": "RxNorm:27392",
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352224,
        "implications": {
            "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "lookupkey": {
            "CYP2D6": "\u22653"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "4.0"
        },
        "allelestatus": {},
        "classification": "Moderate",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "drug": {
            "name": "tropisetron"
        },
        "drugid": "RxNorm:27392",
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352225,
        "implications": {
            "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "lookupkey": {
            "CYP2D6": "4"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "3.5"
        },
        "allelestatus": {},
        "classification": "Moderate",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "drug": {
            "name": "tropisetron"
        },
        "drugid": "RxNorm:27392",
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352226,
        "implications": {
            "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "lookupkey": {
            "CYP2D6": "3.5"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "3.0"
        },
        "allelestatus": {},
        "classification": "Moderate",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "drug": {
            "name": "tropisetron"
        },
        "drugid": "RxNorm:27392",
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352227,
        "implications": {
            "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "lookupkey": {
            "CYP2D6": "3"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "2.5"
        },
        "allelestatus": {},
        "classification": "Moderate",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "drug": {
            "name": "tropisetron"
        },
        "drugid": "RxNorm:27392",
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352228,
        "implications": {
            "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "lookupkey": {
            "CYP2D6": "2.5"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "2.25"
        },
        "allelestatus": {},
        "classification": "Strong",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "drug": {
            "name": "tropisetron"
        },
        "drugid": "RxNorm:27392",
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352229,
        "implications": {
            "CYP2D6": "Normal metabolism"
        },
        "lookupkey": {
            "CYP2D6": "2.25"
        },
        "phenotypes": {
            "CYP2D6": "Normal Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "2.0"
        },
        "allelestatus": {},
        "classification": "Strong",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "drug": {
            "name": "tropisetron"
        },
        "drugid": "RxNorm:27392",
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352230,
        "implications": {
            "CYP2D6": "Normal metabolism"
        },
        "lookupkey": {
            "CYP2D6": "2"
        },
        "phenotypes": {
            "CYP2D6": "Normal Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "1.75"
        },
        "allelestatus": {},
        "classification": "Strong",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "drug": {
            "name": "tropisetron"
        },
        "drugid": "RxNorm:27392",
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352231,
        "implications": {
            "CYP2D6": "Normal metabolism"
        },
        "lookupkey": {
            "CYP2D6": "1.75"
        },
        "phenotypes": {
            "CYP2D6": "Normal Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "1.5"
        },
        "allelestatus": {},
        "classification": "Strong",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "drug": {
            "name": "tropisetron"
        },
        "drugid": "RxNorm:27392",
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352232,
        "implications": {
            "CYP2D6": "Normal metabolism"
        },
        "lookupkey": {
            "CYP2D6": "1.5"
        },
        "phenotypes": {
            "CYP2D6": "Normal Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "1.25"
        },
        "allelestatus": {},
        "classification": "Strong",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "drug": {
            "name": "tropisetron"
        },
        "drugid": "RxNorm:27392",
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352233,
        "implications": {
            "CYP2D6": "Normal metabolism"
        },
        "lookupkey": {
            "CYP2D6": "1.25"
        },
        "phenotypes": {
            "CYP2D6": "Normal Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "1.0"
        },
        "allelestatus": {},
        "classification": "No recommendation.",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "drug": {
            "name": "tropisetron"
        },
        "drugid": "RxNorm:27392",
        "drugrecommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352234,
        "implications": {
            "CYP2D6": "Very limited data available for CYP2D6 intermediate metabolizers"
        },
        "lookupkey": {
            "CYP2D6": "1"
        },
        "phenotypes": {
            "CYP2D6": "Intermediate Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "0.75"
        },
        "allelestatus": {},
        "classification": "No recommendation.",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "drug": {
            "name": "tropisetron"
        },
        "drugid": "RxNorm:27392",
        "drugrecommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352235,
        "implications": {
            "CYP2D6": "Very limited data available for CYP2D6 intermediate metabolizers"
        },
        "lookupkey": {
            "CYP2D6": "0.75"
        },
        "phenotypes": {
            "CYP2D6": "Intermediate Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "0.5"
        },
        "allelestatus": {},
        "classification": "No recommendation.",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "drug": {
            "name": "tropisetron"
        },
        "drugid": "RxNorm:27392",
        "drugrecommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352236,
        "implications": {
            "CYP2D6": "Very limited data available for CYP2D6 intermediate metabolizers"
        },
        "lookupkey": {
            "CYP2D6": "0.5"
        },
        "phenotypes": {
            "CYP2D6": "Intermediate Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "0.25"
        },
        "allelestatus": {},
        "classification": "No recommendation.",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "drug": {
            "name": "tropisetron"
        },
        "drugid": "RxNorm:27392",
        "drugrecommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352237,
        "implications": {
            "CYP2D6": "Very limited data available for CYP2D6 intermediate metabolizers"
        },
        "lookupkey": {
            "CYP2D6": "0.25"
        },
        "phenotypes": {
            "CYP2D6": "Intermediate Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "0.0"
        },
        "allelestatus": {},
        "classification": "No recommendation.",
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "drug": {
            "name": "tropisetron"
        },
        "drugid": "RxNorm:27392",
        "drugrecommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352238,
        "implications": {
            "CYP2D6": "Very limited data available for CYP2D6 poor metabolizers"
        },
        "lookupkey": {
            "CYP2D6": "0"
        },
        "phenotypes": {
            "CYP2D6": "Poor Metabolizer"
        },
        "population": "general",
        "version": 1
    },
    {
        "activityscore": {
            "CYP2D6": "n/a"
        },
        "allelestatus": {},
        "classification": "No recommendation.",
        "comments": "n/a",
        "drug": {
            "name": "tropisetron"
        },
        "drugid": "RxNorm:27392",
        "drugrecommendation": "No recommendation.",
        "guideline": {
            "name": "CYP2D6 and Ondansetron and Tropisetron"
        },
        "guidelineid": 100417,
        "id": 1352239,
        "implications": {
            "CYP2D6": "n/a"
        },
        "lookupkey": {
            "CYP2D6": "n/a"
        },
        "phenotypes": {
            "CYP2D6": "Indeterminate"
        },
        "population": "general",
        "version": 1
    }
]